Jagsonpal Pharmaceuticals Limited reported earnings results for the third quarter and nine months ended December 31, 2023. For the third quarter, the company reported sales was INR 472.34 million compared to INR 601.4 million a year ago. Revenue was INR 497.55 million compared to INR 618.81 million a year ago. Net income was INR 39.63 million compared to INR 77.85 million a year ago. Basic earnings per share from continuing operations was INR 1.48 compared to INR 2.97 a year ago. Diluted earnings per share from continuing operations was INR 1.47 compared to INR 2.97 a year ago.
For the nine months, sales was INR 1,652.16 million compared to INR 1,812.63 million a year ago. Revenue was INR 1,720.08 million compared to INR 1,841.82 million a year ago. Net income was INR 189.14 million compared to INR 211.18 million a year ago. Basic earnings per share from continuing operations was INR 7.18 compared to INR 8.06 a year ago. Diluted earnings per share from continuing operations was INR 7.15 compared to INR 8.06 a year ago.